|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
|
IL115880A
(en)
*
|
1995-11-06 |
2008-11-26 |
Hadasit Med Res Service |
Construct for infecting mammalian cells comprising the sv40 vp1 capsid protein and a histone - free constituent, methods of construction and uses thereof
|
|
WO1997040163A1
(en)
*
|
1996-04-19 |
1997-10-30 |
Metin Colpan |
Nucleic acid vaccination for parvoviral infections
|
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
|
AU771545B2
(en)
*
|
1996-09-11 |
2004-03-25 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
AAV4 vector and uses thereof
|
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
|
CA2270285A1
(en)
*
|
1996-12-18 |
1998-06-25 |
Targeted Genetics Corporation |
Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
|
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
|
US6642051B1
(en)
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
|
DE69918090T2
(de)
*
|
1998-04-24 |
2005-06-16 |
University Of Florida, Gainesville |
Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
|
|
GB9811171D0
(en)
*
|
1998-05-22 |
1998-07-22 |
Royal Free Hosp School Med |
Viral vector
|
|
DE69939169D1
(de)
*
|
1998-05-28 |
2008-09-04 |
Us Gov Health & Human Serv |
Aav5 vektoren und deren verwendung
|
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
|
DE19827457C1
(de)
|
1998-06-19 |
2000-03-02 |
Medigene Ag |
Strukturprotein von AAV, seine Herstellung und Verwendung
|
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
EP1135468B1
(de)
*
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
|
US20040043488A1
(en)
*
|
1999-02-17 |
2004-03-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Adeno-associated viral gene-transfer vector system
|
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
|
US6498244B1
(en)
*
|
1999-05-28 |
2002-12-24 |
Cell Genesys, Inc. |
Adeno-associated virus capsid immunologic determinants
|
|
US7314912B1
(en)
|
1999-06-21 |
2008-01-01 |
Medigene Aktiengesellschaft |
AAv scleroprotein, production and use thereof
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
DE19933719A1
(de)
|
1999-07-19 |
2001-01-25 |
Medigene Ag |
Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
|
|
AU3988401A
(en)
*
|
2000-02-25 |
2001-09-03 |
Ludwig Inst Cancer Res |
Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
|
|
US6855314B1
(en)
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
|
US6468524B1
(en)
|
2000-03-22 |
2002-10-22 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
AAV4 vector and uses thereof
|
|
JP2004514407A
(ja)
*
|
2000-04-28 |
2004-05-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
|
|
US6368602B1
(en)
*
|
2000-06-16 |
2002-04-09 |
Hadasit Medical Research Services And Development Ltd |
Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
|
|
WO2002013758A2
(fr)
*
|
2000-08-18 |
2002-02-21 |
Gencell S.A. |
Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
|
|
FR2813085A1
(fr)
*
|
2000-08-18 |
2002-02-22 |
Aventis Pharma Sa |
Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
|
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
|
EP1572893B1
(de)
*
|
2001-11-09 |
2009-01-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Produktion von adenoassoziiertem virus in insektenzellen
|
|
CN103589692B
(zh)
|
2001-11-13 |
2018-07-24 |
宾夕法尼亚大学托管会 |
检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
|
|
EP1463805B1
(de)
|
2001-12-17 |
2014-10-22 |
The Trustees of The University of Pennsylvania |
Sequenzen des adeno-assoziierten virus (aav) serotyp 9, diese enthaltende vektoren und verwendungen dafür
|
|
DK2359869T3
(en)
|
2001-12-17 |
2019-04-15 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
|
|
AU2003221733A1
(en)
*
|
2002-04-17 |
2003-11-03 |
University Of Florida Research Foundation, Inc. |
Improved raav vectors
|
|
US20060093589A1
(en)
*
|
2004-02-19 |
2006-05-04 |
Warrington Kenneth H |
Vp2-modified raav vector compositions and uses therefor
|
|
SI1496944T1
(sl)
*
|
2002-05-01 |
2009-02-28 |
Univ Florida |
Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
|
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
|
CA2538843A1
(en)
*
|
2003-09-12 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Animal model for protease activity and liver damage
|
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
|
US7422741B2
(en)
|
2004-03-05 |
2008-09-09 |
Vegenics Limited |
VEGFR-3 fusion proteins
|
|
US7582442B2
(en)
|
2004-03-16 |
2009-09-01 |
The Regents Of The University Of Michigan |
Methods and compositions for using aleveolar macrophage phospholipase A2
|
|
US7319015B2
(en)
*
|
2004-03-16 |
2008-01-15 |
The Regents Of The University Of Michigan |
Methods and compositions for using alveolar macrophage phospholipase A2
|
|
US7964196B2
(en)
*
|
2004-05-25 |
2011-06-21 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
|
US20050281786A1
(en)
*
|
2004-06-18 |
2005-12-22 |
David Poulsen |
AAV mediated gene delivery to cochlear cells
|
|
US20090233986A1
(en)
*
|
2004-07-27 |
2009-09-17 |
Mount Sinai School Of Medicine |
Methods and compositions for using sax2
|
|
FI20050753A7
(fi)
|
2004-09-03 |
2006-03-04 |
Licentia Oy |
Uudet peptidit
|
|
EP1828390B1
(de)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimäre vektoren
|
|
WO2006101629A2
(en)
*
|
2005-02-17 |
2006-09-28 |
Vertex Pharmaceuticals Incorporated |
SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
|
|
US8283151B2
(en)
|
2005-04-29 |
2012-10-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
|
|
US7972813B2
(en)
*
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
|
US20080200408A1
(en)
*
|
2005-09-30 |
2008-08-21 |
Mccormack Kenneth |
Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
|
|
PL1969003T3
(pl)
|
2005-12-14 |
2011-05-31 |
Herantis Pharma Plc |
Zastosowanie białka czynnika neurotroficznego
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
US20090214496A1
(en)
*
|
2006-01-30 |
2009-08-27 |
Licentia Ltd. |
Bmx/etk tyrosine kinase gene therapy materials and methods
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
JP2009533350A
(ja)
*
|
2006-04-07 |
2009-09-17 |
キメロス, インコーポレイテッド |
B細胞悪性疾患を処置するための組成物および方法
|
|
ES2429225T3
(es)
|
2006-05-17 |
2013-11-13 |
The Ludwig Institute For Cancer Research |
Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
|
|
CN101511373B
(zh)
|
2006-06-19 |
2015-12-09 |
阿斯克肋匹奥生物制药公司 |
用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
|
|
ES2385679T3
(es)
*
|
2006-08-24 |
2012-07-30 |
Virovek, Inc. |
Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
|
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
|
EP2012122A1
(de)
*
|
2007-07-06 |
2009-01-07 |
Medigene AG |
Strukturproteine von mutierten Parvoviren als Impfstoffe
|
|
FI20070808A0
(fi)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
GDNF:n silmukointivariantit ja niiden käytöt
|
|
US20090196854A1
(en)
*
|
2008-02-04 |
2009-08-06 |
Kytos Biosystems S.A. |
Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
|
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010002895A2
(en)
|
2008-06-30 |
2010-01-07 |
The Regents Of The University Of Michigan |
Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
|
|
EP2396343B1
(de)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
|
|
EP2408475B1
(de)
|
2009-03-18 |
2017-11-15 |
Wake Forest University Health Sciences |
Flagellin-fusionsproteine und ihre verwendung zur auslösung von immunantworten gegen pseudomonas aeruginosa
|
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
CA2826273C
(en)
|
2011-02-10 |
2021-11-02 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
EP3219313B1
(de)
|
2011-04-18 |
2020-10-28 |
National Center of Neurology and Psychiatry |
Arzneimittelabgabepartikel und verfahren zur herstellung davon
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
ES2748577T3
(es)
|
2011-05-19 |
2020-03-17 |
Univ Michigan Regents |
Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
|
|
CA2847888A1
(en)
|
2011-09-09 |
2013-03-14 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
|
EP2785683B1
(de)
|
2011-11-30 |
2020-02-05 |
Ludwig Institute for Cancer Research Ltd. |
Inkt-zellmodulatoren und verwendungsverfahren dafür
|
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
|
AU2012348332B2
(en)
|
2011-12-08 |
2017-06-29 |
Haifeng Chen |
Vectors harboring toxic genes, methods and uses therefor
|
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
|
EP4124346A3
(de)
|
2012-06-19 |
2023-04-19 |
University of Florida Research Foundation, Inc. |
Zusammensetzungen und verfahren zur behandlung von krankheiten
|
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
|
WO2014039916A1
(en)
|
2012-09-06 |
2014-03-13 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
|
PL2900686T3
(pl)
|
2012-09-28 |
2021-01-25 |
The University Of North Carolina At Chapel Hill |
Wektory aav ukierunkowane na oligodendrocyty
|
|
MY170528A
(en)
|
2013-02-18 |
2019-08-09 |
Vegenics Pty Ltd |
Vegfr-3 ligand binding molecules and uses thereof
|
|
WO2014159546A1
(en)
|
2013-03-14 |
2014-10-02 |
Asklepios Biopharmaceutical, Inc. |
Modified soluble vegf receptor-1 genes and vectors for gene therapy
|
|
EP2970966A4
(de)
|
2013-03-15 |
2016-10-26 |
Univ North Carolina |
Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
|
|
ES2926774T3
(es)
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
|
ES2813698T3
(es)
|
2013-09-12 |
2021-03-24 |
Biomarin Pharm Inc |
Vectores de AAV que comprenden un gen que codifica el factor VIII
|
|
HUE052676T2
(hu)
|
2013-10-11 |
2021-05-28 |
Massachusetts Eye & Ear Infirmary |
Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
BR112016020688B1
(pt)
|
2014-03-09 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
|
|
JP6756700B2
(ja)
|
2014-03-18 |
2020-09-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
US11555059B2
(en)
|
2014-04-25 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
LDLR variants and their use in compositions for reducing cholesterol levels
|
|
CR20160519A
(es)
|
2014-05-13 |
2017-01-27 |
The Trustees Of The Univ Of Pennysylvania |
Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US10973931B2
(en)
|
2014-09-16 |
2021-04-13 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
EP3215191B1
(de)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Aadc-polynukleotide zur behandlung von morbus parkinson
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
AU2015349759B2
(en)
|
2014-11-21 |
2022-01-06 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
EP3242945B1
(de)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
|
|
AU2016206624B2
(en)
|
2015-01-14 |
2020-08-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
KR102554850B1
(ko)
|
2015-02-06 |
2023-07-13 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3256170B1
(de)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Zusammensetzungen und verfahren zur transitorischen freisetzung von polypeptiden
|
|
US10273483B2
(en)
|
2015-04-08 |
2019-04-30 |
The University Of Chicago |
Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
JP6851319B2
(ja)
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
|
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
|
ES3009026T3
(en)
|
2015-07-22 |
2025-03-25 |
Univ Duke |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
KR20240132120A
(ko)
|
2015-08-25 |
2024-09-02 |
듀크 유니버시티 |
Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
|
|
HK1257024A1
(zh)
|
2015-08-31 |
2019-10-11 |
宾夕法尼亚大学 |
用於治疗伴侣动物的aav-epo
|
|
JP2018535929A
(ja)
|
2015-09-24 |
2018-12-06 |
バイオマリン ファーマシューティカル インコーポレイテッド |
アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
|
|
EP3359663A4
(de)
|
2015-09-24 |
2019-08-14 |
The Trustees of The University of Pennsylvania |
Zusammensetzung und verfahren zur behandlung einer komplementvermittelten erkrankung
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
JP7059179B2
(ja)
|
2015-10-20 |
2022-04-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
遺伝子操作のための方法及び製品
|
|
EP4636083A3
(de)
|
2015-10-20 |
2026-01-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und produkte für gentechnologie
|
|
EP3364997B1
(de)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gentherapie zur behandlung von morbus canavan
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
US11135313B2
(en)
|
2015-10-28 |
2021-10-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
SG10201912763QA
(en)
|
2015-11-05 |
2020-02-27 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
TN2018000163A1
(en)
|
2015-11-12 |
2019-10-04 |
Res Inst Nationwide Childrens Hospital |
Methods of treating muscular dystrophy
|
|
CN108463211B
(zh)
|
2015-11-16 |
2022-09-27 |
全国儿童医院研究所 |
用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
|
|
EP4085934A1
(de)
|
2015-12-11 |
2022-11-09 |
The Trustees of The University of Pennsylvania |
Gentherapeutische behandlung der familiären hypercholesterinämie
|
|
AU2016370590B2
(en)
|
2015-12-14 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
|
US11124546B2
(en)
|
2015-12-14 |
2021-09-21 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
|
CN109069668B
(zh)
|
2015-12-14 |
2023-04-18 |
宾夕法尼亚州大学信托人 |
用于眼病的基因疗法
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017165859A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
EP3440210A4
(de)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
Zusammensetzungen und verfahren zur selektiven hemmung der expression des grainyhead-like-proteins
|
|
EP3443081A4
(de)
|
2016-04-13 |
2019-10-30 |
Duke University |
Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3449250B1
(de)
|
2016-04-28 |
2020-11-04 |
Indiana University Research & Technology Corporation |
Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
|
|
EP3448987A4
(de)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
|
EP3448874A4
(de)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
US11197936B2
(en)
|
2016-07-08 |
2021-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Cpf1に基づくゲノム編集の治療適用
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
JP6994018B2
(ja)
|
2016-07-26 |
2022-01-14 |
バイオマリン ファーマシューティカル インコーポレイテッド |
新規アデノ随伴ウイルスキャプシドタンパク質
|
|
HUE053747T2
(hu)
|
2016-08-15 |
2021-07-28 |
Genzyme Corp |
Eljárások AAV kimutatására
|
|
EP3831281B1
(de)
|
2016-08-30 |
2026-02-25 |
The Regents of The University of California |
Vorrichtungen und systeme für biomedizinische zielführung und verabreichung
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
ES2931960T3
(es)
|
2016-12-01 |
2023-01-05 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de enfermedades degenerativas retinianas
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
TW201837170A
(zh)
|
2017-02-28 |
2018-10-16 |
賓州大學委員會 |
新穎aav媒介的流感疫苗
|
|
RS65241B1
(sr)
|
2017-02-28 |
2024-03-29 |
Univ Pennsylvania |
Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
|
|
WO2018160849A1
(en)
|
2017-03-01 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
US10550405B2
(en)
|
2017-03-15 |
2020-02-04 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
WO2018170310A1
(en)
*
|
2017-03-15 |
2018-09-20 |
The University Of North Carolina At Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
EP3618839A4
(de)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
AU2018264996A1
(en)
|
2017-05-09 |
2019-12-05 |
University Of Massachusetts |
Methods of treating Amyotrophic Lateral Sclerosis (ALS)
|
|
WO2018209154A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses
|
|
CA3062614A1
(en)
*
|
2017-05-10 |
2018-11-15 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
BR112019023303A2
(pt)
|
2017-05-11 |
2020-06-16 |
The Trustees Of The University Of Pennsylvania |
Terapia de gene para lipofuscinoses ceroides neuronais
|
|
BR112019024608A2
(pt)
|
2017-05-24 |
2020-06-23 |
Universitat Autonoma De Barcelona |
Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21)
|
|
KR102765034B1
(ko)
|
2017-05-24 |
2025-02-11 |
유니버시타트 아우토노마 데 바르셀로나 |
섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
|
|
US11793887B2
(en)
|
2017-05-31 |
2023-10-24 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
WO2018226602A1
(en)
|
2017-06-05 |
2018-12-13 |
Research Institute At Nationwide Children's Hospital |
Enhanced modified viral capsid proteins
|
|
US11827898B2
(en)
|
2017-06-14 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
EP4467146A3
(de)
|
2017-09-15 |
2025-05-07 |
King's College London |
Zusammensetzungen und verfahren zur verbesserung von gamma-delta-t-zellen im darm
|
|
US11668719B2
(en)
|
2017-09-20 |
2023-06-06 |
The Trustees Of Indiana University |
Methods for resolving lipoproteins with mass spectrometry
|
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
AU2018350700B2
(en)
|
2017-10-16 |
2025-04-24 |
VeonGen Therapeutics GmbH |
AAV vectors
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
AU2018354195A1
(en)
*
|
2017-10-23 |
2020-06-04 |
Prevail Therapeutics, Inc. |
Gene therapies for neurodegenerative disease
|
|
CA3086045A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
|
US11232941B2
(en)
|
2018-01-12 |
2022-01-25 |
The Trustees Of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
|
AU2019216257B2
(en)
|
2018-01-31 |
2025-11-20 |
Research Institute At Nationwide Children's Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2C
|
|
EP3768695A4
(de)
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
Neuartige adeno-assoziierte virus (aav)-vektoren, aav-vektoren mit reduzierter kapsiddeamidierung und verwendungen davon
|
|
CA3092107A1
(en)
|
2018-02-28 |
2019-09-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
EP3762500A1
(de)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
|
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
IT201800004253A1
(it)
|
2018-04-05 |
2019-10-05 |
|
Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
KR20210008501A
(ko)
|
2018-05-09 |
2021-01-22 |
바이오마린 파머수티컬 인크. |
페닐케톤뇨증을 치료하는 방법
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
CN112424345A
(zh)
|
2018-05-14 |
2021-02-26 |
生物马林药物股份有限公司 |
Aav载体在青少年对象中的稳定表达
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
US11227759B2
(en)
|
2018-06-04 |
2022-01-18 |
The Trustees Of Indiana University |
Ion trap array for high throughput charge detection mass spectrometry
|
|
KR102742958B1
(ko)
|
2018-06-04 |
2024-12-16 |
더 트러스티즈 오브 인디애나 유니버시티 |
실시간 분석 및 신호 최적화를 통한 전하 검출 질량 분광분석법
|
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
|
WO2019236141A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for capturing ions in an electrostatic linear ion trap
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
US12258395B2
(en)
|
2018-06-11 |
2025-03-25 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for treating stress-related disorders and cancer
|
|
JP7428664B2
(ja)
|
2018-06-12 |
2024-02-06 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
IL279789B2
(en)
|
2018-06-29 |
2026-04-01 |
Res Inst Nationwide Childrens Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3860659A1
(de)
|
2018-10-01 |
2021-08-11 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen zur behandlung von gm1-gangliosidose
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
CN113574632B
(zh)
|
2018-11-20 |
2024-07-30 |
印地安纳大学理事会 |
用于单粒子质谱分析的轨道阱
|
|
IL283452B2
(en)
|
2018-11-26 |
2026-04-01 |
Univ Barcelona Autonoma |
FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
|
|
AU2019392058B2
(en)
|
2018-12-03 |
2024-12-05 |
The Trustees Of Indiana University |
Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
MX2021010134A
(es)
|
2019-02-22 |
2021-09-23 |
Univ Pennsylvania |
Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
|
|
KR20210133242A
(ko)
|
2019-02-26 |
2021-11-05 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
|
|
EP3931337A1
(de)
|
2019-02-26 |
2022-01-05 |
The Trustees of The University of Pennsylvania |
Zur behandlung von morbus krabbe nützliche zusammensetzungen
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
|
|
WO2020219527A1
(en)
|
2019-04-23 |
2020-10-29 |
The Trustees Of Indiana University |
Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
|
|
AU2020263392A1
(en)
|
2019-04-26 |
2021-10-28 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding AAV2.5 vector
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
JP7715640B2
(ja)
|
2019-05-03 |
2025-07-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
異染性白質ジストロフィーの治療に有用な組成物
|
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
|
WO2020232044A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
|
EP3976087A1
(de)
|
2019-05-31 |
2022-04-06 |
Universitat Autònoma De Barcelona |
Insulingentherapie
|
|
KR20220031000A
(ko)
|
2019-07-03 |
2022-03-11 |
각꼬호우징 닛뽄 이까다이가꾸 |
핵산 봉입aav 중공입자의 제조방법
|
|
ES2948620T3
(es)
|
2019-07-10 |
2023-09-14 |
Masonic Medical Res Laboratory |
Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
|
|
EP4007814A1
(de)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Verfahren zur behandlung von hörverlust unter verwendung eines sekretierten zielproteins
|
|
EP4010465A1
(de)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
|
CA3150964A1
(en)
|
2019-08-21 |
2021-02-25 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
|
EP4022070A1
(de)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Kontrollierte expression viraler proteine
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
US12112936B2
(en)
|
2019-09-25 |
2024-10-08 |
The Trustees Of Indiana University |
Apparatus and method for pulsed mode charge detection mass spectrometry
|
|
CA3153782A1
(en)
|
2019-09-27 |
2022-03-08 |
Biomarin Pharmaceutical Inc. |
Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
|
|
JP7659325B2
(ja)
|
2019-10-10 |
2025-04-09 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
粒子を識別、選択、および純化するためのシステムおよび方法
|
|
CN114787180A
(zh)
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
MX2022004353A
(es)
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
US20230340078A1
(en)
|
2019-11-14 |
2023-10-26 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with liver-specific gene therapy vectors
|
|
KR20220112283A
(ko)
|
2019-12-10 |
2022-08-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
Hunter 질환 치료용 아데노-연합된 바이러스 벡터
|
|
JP7690209B2
(ja)
|
2019-12-18 |
2025-06-10 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
電荷測定装置を有する質量分析計
|
|
BR112022011916A2
(pt)
|
2019-12-19 |
2022-09-06 |
Univ Pennsylvania |
Composições para tratar a ataxia de friedreich
|
|
KR102923996B1
(ko)
|
2020-02-03 |
2026-02-05 |
더 트러스티즈 오브 인디애나 유니버시티 |
전하 검출 질량 분석법을 위한 신호들의 시간-도메인 분석
|
|
CA3170169A1
(en)
*
|
2020-02-07 |
2021-08-12 |
Vecprobio, Inc. |
Recombinant adeno-associated viral vectors in plants
|
|
WO2021183895A1
(en)
|
2020-03-13 |
2021-09-16 |
Biomarin Pharmaceutical Inc. |
Treatment of fabry disease with aav gene therapy vectors
|
|
US20230158173A1
(en)
|
2020-03-20 |
2023-05-25 |
University Of Florida Research Foundation, Inc. |
Gene therapy for cockayne syndrome
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
TW202144575A
(zh)
|
2020-04-03 |
2021-12-01 |
美商拜奧馬林製藥公司 |
使用aav及治療調配物之苯酮尿症治療
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
CA3177268A1
(en)
|
2020-05-05 |
2021-11-11 |
The University Of North Carolina At Chapel Hill |
Modified adeno-associated virus 5 capsids and uses thereof
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
KR20230041965A
(ko)
|
2020-05-13 |
2023-03-27 |
아카우오스, 인크. |
Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
CN115916985A
(zh)
|
2020-05-26 |
2023-04-04 |
巴塞罗那自治大学 |
用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
EP4192514A1
(de)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
|
JP2023542614A
(ja)
|
2020-08-19 |
2023-10-11 |
サレプタ セラピューティクス, インコーポレイテッド |
レット症候群の治療のためのアデノ随伴ウイルスベクター
|
|
US20230372539A1
(en)
|
2020-08-24 |
2023-11-23 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
AU2021332331A1
(en)
|
2020-08-26 |
2023-03-09 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of GRN-associated adult-onset neurodegeneration
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
JP2023544803A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Cln2疾患の眼症状に対する遺伝子療法
|
|
JP2023548746A
(ja)
|
2020-10-13 |
2023-11-21 |
クリヤ セラピューティクス インコーポレイテッド |
サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
|
|
WO2022082109A1
(en)
|
2020-10-18 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
CN116490514A
(zh)
|
2020-10-28 |
2023-07-25 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
|
MX2023005113A
(es)
|
2020-10-29 |
2023-08-04 |
Univ Pennsylvania |
Cápsides de aav y composiciones que las contienen.
|
|
KR20230078805A
(ko)
|
2020-11-02 |
2023-06-02 |
바이오마린 파머수티컬 인크. |
아데노-연관 바이러스의 농축 공정
|
|
AU2021375404A1
(en)
|
2020-11-03 |
2023-06-08 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
AR124216A1
(es)
|
2020-12-01 |
2023-03-01 |
Univ Pennsylvania |
Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
|
|
JP2024503234A
(ja)
|
2020-12-23 |
2024-01-25 |
ファイザー・インク |
親和性クロマトグラフィーによるaavベクターの精製方法
|
|
CN117157108A
(zh)
|
2020-12-29 |
2023-12-01 |
阿库斯股份有限公司 |
用于治疗clrn1相关听力损失和/或视力损失的组合物和方法
|
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向t細胞之aav載體
|
|
CA3206107A1
(en)
|
2021-01-26 |
2022-08-04 |
Brian Furmanski |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
CA3206590A1
(en)
|
2021-01-30 |
2022-08-04 |
Maria Fatima Bosch Tubert |
Gene therapy for monogenic diabetes
|
|
MX2023008826A
(es)
|
2021-02-01 |
2023-09-15 |
Regenxbio Inc |
Terapia génica para lipofuscinosis neuronal ceroidea.
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
US11760788B2
(en)
|
2021-03-02 |
2023-09-19 |
Pathways Neuro Pharma, Inc. |
Neuroreceptor compositions and methods of use
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4301861A1
(de)
|
2021-03-03 |
2024-01-10 |
Shape Therapeutics Inc. |
Auxotrophe zellen zur virusproduktion sowie zusammensetzungen und verfahren zur herstellung
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4301860A1
(de)
|
2021-03-04 |
2024-01-10 |
Kriya Therapeutics, Inc. |
Virale vektorkonstrukte mit dna zur hemmung toll-ähnlicher rezeptoren und verfahren zur verwendung davon
|
|
IL307633A
(en)
|
2021-04-12 |
2023-12-01 |
Univ Pennsylvania |
Useful preparations in the treatment of spinal muscular atrophy (SBMA)
|
|
WO2022221462A1
(en)
|
2021-04-13 |
2022-10-20 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
|
|
JP2024515626A
(ja)
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル, インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン
|
|
WO2022226296A2
(en)
|
2021-04-23 |
2022-10-27 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
|
EP4330411B1
(de)
|
2021-04-27 |
2026-03-18 |
4D Molecular Therapeutics Inc. |
Zusammensetzungen und verfahren zur behandlung von augenerkrankungen im zusammenhang mit angiogenese
|
|
EP4089171A1
(de)
|
2021-05-12 |
2022-11-16 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Rekombinante tert-codierende virale genome und vektoren
|
|
MX2023015329A
(es)
|
2021-06-22 |
2024-01-23 |
Pfizer |
Produccion de vector de virus adeno-asociado en celulas de insecto.
|
|
EP4384195A2
(de)
|
2021-08-11 |
2024-06-19 |
King's College London |
Zusammensetzungen und verfahren zur verbesserten behandlung von erkrankungen mit einfluss auf das zentrale nervensystem
|
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
|
US20240343787A1
(en)
|
2021-08-20 |
2024-10-17 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
US20240384242A1
(en)
|
2021-09-03 |
2024-11-21 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
EP4396201A1
(de)
|
2021-09-03 |
2024-07-10 |
BioMarin Pharmaceutical Inc. |
Aav-kapsid-zusammensetzungen und verfahren zur freisetzung
|
|
JP2024534894A
(ja)
|
2021-09-03 |
2024-09-26 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
Aavカプシド組成物及び送達方法
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250288692A1
(en)
|
2021-09-30 |
2025-09-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
TW202332472A
(zh)
|
2021-10-01 |
2023-08-16 |
美商拜奧馬林製藥公司 |
利用aav基因療法載體進行之遺傳性血管水腫治療及治療性調配物
|
|
US20240384298A1
(en)
|
2021-10-02 |
2024-11-21 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
EP4426716A1
(de)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav-kapsidvarianten und verwendungen davon
|
|
US20250002938A1
(en)
|
2021-11-09 |
2025-01-02 |
The Francis Crick Institute Limited |
Viral adaptors and uses thereof
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4433169A1
(de)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav-kapsidvarianten und verwendungen davon
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
CA3240342A1
(en)
|
2021-12-16 |
2023-06-22 |
Gopal SAPKOTA |
Targeted degradation of alpha-synuclein
|
|
JP2025503637A
(ja)
|
2022-01-09 |
2025-02-04 |
クリヤ セラピューティクス, インコーポレイテッド |
治療用抗igf-1r抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
|
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
|
US20250346920A1
(en)
|
2022-01-25 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
AR128422A1
(es)
|
2022-02-02 |
2024-05-08 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
|
TW202342759A
(zh)
|
2022-02-04 |
2023-11-01 |
美商史崔德生物公司 |
重組腺相關病毒載體及其使用方法
|
|
JP2025507338A
(ja)
|
2022-02-08 |
2025-03-18 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavカプシドバリアント及びその使用
|
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
|
EP4504950A1
(de)
|
2022-04-01 |
2025-02-12 |
Takeda Pharmaceutical Company Limited |
Gentherapie für erkrankungen mit zns-manifestationen
|
|
CA3247109A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20250288693A1
(en)
|
2022-04-29 |
2025-09-18 |
Kriya Therapeutics, Inc. |
Insulin and glucokinase gene therapy compositions and its use for treating diabetes
|
|
EP4532515A1
(de)
|
2022-06-02 |
2025-04-09 |
Voyager Therapeutics, Inc. |
Aav-kapsidvarianten und verwendungen davon
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024015966A2
(en)
|
2022-07-15 |
2024-01-18 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav having aav clade d and clade e capsids and compositions containing same
|
|
KR20250052387A
(ko)
|
2022-08-25 |
2025-04-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
파브리병의 치료에서의 사용을 위한 조성물
|
|
EP4584383A1
(de)
|
2022-09-07 |
2025-07-16 |
Universitat Autònoma De Barcelona |
Beta-hexosaminidase-vektoren
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2024054993A1
(en)
|
2022-09-09 |
2024-03-14 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
WO2024056902A2
(en)
|
2022-09-16 |
2024-03-21 |
Christopher Shaw |
Compositions and methods for treating neurological diseases
|
|
UY40443A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía con vectores de genoterapia con aav
|
|
UY40442A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
|
AU2023392154A1
(en)
|
2022-12-14 |
2025-06-26 |
King's College London |
Compositions and methods for treating neurological diseases
|
|
WO2024130007A2
(en)
|
2022-12-16 |
2024-06-20 |
Kriya Therapeutics, Inc. |
Synthetic htert promoters and uses thereof
|
|
EP4634394A2
(de)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Rekombinante aav-mutantenvektoren mit herz- und skelettmuskelspezifischen zielmotiven und zusammensetzungen damit
|
|
WO2024145474A2
(en)
|
2022-12-29 |
2024-07-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2024147114A1
(en)
|
2023-01-06 |
2024-07-11 |
Bloomsbury Genetic Therapies Limited |
Compositions and methods for treating parkinson's disease
|
|
TW202444398A
(zh)
|
2023-01-09 |
2024-11-16 |
美商拜奧馬林製藥公司 |
表觀遺傳修飾劑改善aav基因療法之耐久性
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024161022A2
(en)
|
2023-02-03 |
2024-08-08 |
King's College London |
Compositions and methods for treating neurological diseases
|
|
JP2026509271A
(ja)
|
2023-03-10 |
2026-03-17 |
ダイノ セラピューティクス,インコーポレーテッド |
カプシドポリペプチドおよびその使用方法
|
|
GB202304767D0
(en)
|
2023-03-30 |
2023-05-17 |
Ucl Business Ltd |
Synthetic AAV Capsid
|
|
TW202446959A
(zh)
|
2023-04-03 |
2024-12-01 |
美商德西貝治療公司 |
經修飾之rep—cap質體及其用途
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP4702043A1
(de)
|
2023-04-28 |
2026-03-04 |
Kriya Therapeutics, Inc. |
Chimäre modifizierte ionenkanäle und verwendungen davon zur behandlung von trigeminusnervenerkrankungen
|
|
EP4701634A1
(de)
|
2023-04-28 |
2026-03-04 |
Kriya Therapeutics, Inc. |
Riboswitches zur regulierung der genexpression und therapeutische verfahren zur verwendung davon
|
|
JP2026515815A
(ja)
|
2023-05-03 |
2026-05-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Cdkl5欠損に関連する障害の治療のための組成物及び方法
|
|
WO2024229164A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2024229173A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
IL324036A
(en)
|
2023-05-03 |
2025-12-01 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
JP2026517843A
(ja)
|
2023-05-03 |
2026-06-02 |
アイオーエックス セラピューティクス リミテッド |
Inkt細胞調節剤リポソーム組成物及び使用方法
|
|
JP2026515970A
(ja)
|
2023-05-04 |
2026-05-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavカプシドバリアント及びその使用
|
|
KR20260010739A
(ko)
|
2023-05-11 |
2026-01-21 |
유니버시티 하스피탈즈 클리블랜드 메디컬 센터 |
항불안 치료
|
|
WO2024238591A2
(en)
|
2023-05-15 |
2024-11-21 |
Biomarin Pharmaceutical Inc. |
Methods of treating anti-aav seropositive hemophilia patients
|
|
WO2025007046A1
(en)
|
2023-06-29 |
2025-01-02 |
The Trustees Of The University Of Pennsylvania |
Mutant aav with central nervous system targeting motifs and compositions containing same
|
|
AU2024287813A1
(en)
|
2023-07-07 |
2026-01-22 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|
|
AU2024295314A1
(en)
|
2023-07-11 |
2026-02-05 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding uricase and methods of using the same
|
|
KR20260039752A
(ko)
|
2023-07-13 |
2026-03-20 |
크리야 테라퓨틱스, 인크. |
보체 경로 억제제 융합체 및 그의 사용 방법
|
|
KR20260079164A
(ko)
|
2023-07-21 |
2026-06-01 |
보레아 테라퓨틱스 에스.알.엘. |
표면 변형된 바이러스 캡시드를 제조하는 방법
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025038802A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025038800A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
WO2025038430A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025038796A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025038795A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
KR20260082361A
(ko)
|
2023-08-31 |
2026-06-04 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 폴리펩타이드 및 이의 사용 방법
|
|
WO2025051970A2
(en)
|
2023-09-06 |
2025-03-13 |
Dinaqor Ag |
Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations
|
|
WO2025082618A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
CN122249241A
(zh)
|
2023-11-01 |
2026-06-19 |
克里雅疗法股份有限公司 |
用于治疗糖尿病的aav介导的胰岛素和葡萄糖激酶基因疗法
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
KR20260114566A
(ko)
|
2023-11-14 |
2026-07-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
|
|
TW202540200A
(zh)
|
2023-12-01 |
2025-10-16 |
美商基利科學股份有限公司 |
抗fap-light融合蛋白及其用途
|
|
WO2025122530A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
AR134555A1
(es)
|
2023-12-05 |
2026-01-28 |
Voyager Therapeutics Inc |
Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025126153A2
(en)
|
2023-12-14 |
2025-06-19 |
Aviadobio Ltd. |
Compositions and methods for treating sod1-mediated neurological diseases
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
EP4600264A1
(de)
|
2024-02-08 |
2025-08-13 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Manipulierte typ-2-cytokinsignalisierung zur verbesserung der car-t-zelleffektorfunktionen
|
|
TW202548022A
(zh)
|
2024-03-03 |
2025-12-16 |
美商帕西奇生物公司 |
用於治療神經退化性病症之重組腺相關病毒
|
|
WO2025214477A1
(en)
|
2024-04-12 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Treatment of genetic cardiomyopathies with aav gene therapy vectors
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2025262314A1
(en)
|
2024-06-21 |
2025-12-26 |
Institut National De La Sante Et De La Recherche Medicale |
Methods and products for prime editing genetic engineering
|
|
WO2025262311A1
(en)
|
2024-06-21 |
2025-12-26 |
Institut National De La Sante Et De La Recherche Medicale |
Methods and products for prime editing genetic engineering
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|
|
WO2026028089A1
(en)
|
2024-07-29 |
2026-02-05 |
Novartis Ag |
Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
|
WO2026028137A1
(en)
|
2024-07-31 |
2026-02-05 |
Universitat Autònoma De Barcelona |
Fibroblast growth factor 21 (fgf21) gene therapy
|
|
WO2026064428A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026064442A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026064444A1
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026096611A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096603A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026096600A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096599A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026102000A1
(en)
|
2024-11-06 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2026122921A1
(en)
|
2024-12-05 |
2026-06-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2026122963A1
(en)
|
2024-12-06 |
2026-06-11 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026133103A1
(en)
|
2024-12-16 |
2026-06-25 |
Universitat Autònoma De Barcelona |
Aav vectors for delivery of nucleic acids encoding fgf21 and methods of treating lung diseases using the same
|
|
NL2039429B1
(en)
|
2024-12-20 |
2026-07-13 |
Academisch Ziekenhuis Leiden |
Pabpn1 isoforms for use in therapy
|
|
WO2026151888A1
(en)
|
2025-01-08 |
2026-07-16 |
The Trustees Of The University Of Pennsylvania |
Compositions for treating friedreich's ataxia
|
|
WO2026154123A1
(en)
|
2025-01-17 |
2026-07-23 |
Aviadobio Limited |
Compositions and methods for treating neurological diseases
|